Major Study Published in Nature Medicine on Paige’s Virchow the First Demonstration of Clinical-Grade Performance for Cancer Detection Using a Foundation Model
23 Julio 2024 - 9:00AM
Business Wire
Paige’s collaboration with Microsoft reaches a
new frontier in AI-driven technology for propelling cancer
diagnosis forward
Paige, the pioneer in AI-driven pathology solutions designed to
improve the fight against cancer, in collaboration with Microsoft,
has achieved an important milestone with the publication of a
significant study in Nature Medicine. The study highlights the
capabilities of Virchow, the first million-slide foundation model
for cancer.
Virchow demonstrated clinical grade cancer detection showcasing
state-of-the-art performance across 16 types of cancer, including
seven rare cancers. The extensive dataset used to train Virchow
empowers it to deliver advanced capabilities and accuracy that
allow for the ability to create novel applications in cancer
diagnosis that previously weren’t possible due to limited data.
Virchow works by breaking down each gigapixel H&E slide into
thousands of image tiles and characterizing intricate cancer
patterns that may not be visible to the human eye. This is made
possible by self-supervised learning, which does not require
task-specific data and can leverage the information gained from
billions of image tiles extracted from 1.5 million whole slides,
containing diverse cancer subtypes.
“Today marks another historic achievement for Paige. The
publication of our Virchow Foundation Model in Nature Medicine is a
testament to our team's dedication and expertise in developing
transformative AI for healthcare,” said Razik Yousfi, Senior Vice
President of Technology at Paige. “Virchow's ability to detect,
analyze and characterize diverse cancer types, including rare
cancers, exemplifies its extraordinary power and unprecedented
potential to unlock new insights into cancer.”
“As Paige continues to lead in healthcare technology and machine
learning, with the creation of the world’s first FDA-approved AI
model for pathology and now, with a prestigious scholarly journal
publication of the industry’s first million-slide foundation model
for cancer, I am both proud and inspired,” said Thomas Fuchs,
Dr.Sc., Founder and Chief Scientist of Paige. “The Virchow
Foundation Model is just the beginning, ushering in a future of
revolutionary discoveries in cancer detection and treatment.”
In addition to cancer detection, the study also highlights
Virchow's state-of-the-art performance across a variety of
biomarker prediction tasks. "Biomarker prediction is crucial for
tailoring treatments to individual patients and sets the path for
personalized precision medicine," explained Dr. Siqi Liu, PhD,
Director of AI Science at Paige. "Virchow's superior performance in
biomarker prediction tasks across multiple tissue types
demonstrates its transformative potential in clinical and
pharmaceutical settings."
The lessons learned in this study demonstrate the power of the
latest advances in AI. “Scaling has driven significant progress in
AI, and our work with Paige demonstrates its crucial role in
pathology as well,” noted Jonathan Carlson, Managing Director of
Microsoft Research Health Futures. “By developing a million-slide
foundation model, we achieved unprecedented accuracy and
capabilities, particularly benefiting patients with rare cancers,
where traditional methods lack the predictive power needed for
informed decisions.”
Empowered by this technology, Paige has made significant strides
in developing transformative products such as Paige Pan Cancer
Suite, a single application capable of detecting cancers across the
broad array of tissue types, and PRISM, a multi-modal, slide-level
Foundation Model providing comprehensive written diagnostic
assessments.
Paige continues to lead the charge in expanding Virchow's
capabilities with ongoing developments. For more information on
Virchow or Paige’s pioneering advancements in AI-driven pathology,
please email bd@paige.ai
About Paige
Paige uses the power of AI to drive a new era of cancer
discovery and treatment. To improve the lives of patients with
cancer, Paige has created AI technology and cloud-based platform
that transforms AI development, pathologists' workflow and
increases diagnostic confidence as well as productivity, all on a
global scale. Paige is the first company to receive FDA approval
for a clinical AI application in digital pathology. The same Paige
technology empowers pharmaceutical companies to more effectively
evaluate drug discovery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723996420/en/
Cindi Goodsell | Stanton cgoodsell@stantonprm.com